Life Biosciences

Headquarters: Boston, Massachusetts, USA Founded: 2018 Status: Clinical/Preclinical Focus: Age-related diseases, Neurodegeneration, Ophthalmology Ticker: NASDAQ: LIFE[@life2026]

Overview

Life Biosciences is a biotechnology company focused on developing therapeutics for age-related diseases, with a particular emphasis on neurodegeneration and ocular diseases. Founded in 2018, the company takes a multi-target approach to address the underlying mechanisms of aging, including mitochondrial dysfunction, protein aggregation, and cellular senescence[@life2026a].

The company's name reflects its mission to extend healthy life by targeting the fundamental biological processes that drive age-related decline. Life Biosciences operates at the intersection of longevity science and pharmaceutical development, leveraging insights from aging research to develop disease-modifying therapies for conditions like Alzheimer's disease, Parkinson's disease, and age-related macular degeneration.

Business Model and Strategy

Life Biosciences operates as a clinical-stage biotechnology company with a focus on:

Platform-based drug discovery: Developing proprietary molecules targeting multiple hallmarks of aging

Indication expansion: Repositioning pipeline assets across multiple age-related conditions

Academic partnerships: Collaborating with leading research institutions on mechanism of action

Competitive Positioning

Life Biosciences competes with several longevity-focused biotech companies including:

...

Headquarters: Boston, Massachusetts, USA Founded: 2018 Status: Clinical/Preclinical Focus: Age-related diseases, Neurodegeneration, Ophthalmology Ticker: NASDAQ: LIFE[@life2026]

Overview

Life Biosciences is a biotechnology company focused on developing therapeutics for age-related diseases, with a particular emphasis on neurodegeneration and ocular diseases. Founded in 2018, the company takes a multi-target approach to address the underlying mechanisms of aging, including mitochondrial dysfunction, protein aggregation, and cellular senescence[@life2026a].

The company's name reflects its mission to extend healthy life by targeting the fundamental biological processes that drive age-related decline. Life Biosciences operates at the intersection of longevity science and pharmaceutical development, leveraging insights from aging research to develop disease-modifying therapies for conditions like Alzheimer's disease, Parkinson's disease, and age-related macular degeneration.

Business Model and Strategy

Life Biosciences operates as a clinical-stage biotechnology company with a focus on:

Platform-based drug discovery: Developing proprietary molecules targeting multiple hallmarks of aging

Indication expansion: Repositioning pipeline assets across multiple age-related conditions

Academic partnerships: Collaborating with leading research institutions on mechanism of action

Competitive Positioning

Life Biosciences competes with several longevity-focused biotech companies including:

• Calico Life Sciences (Alphabet subsidiary)
• Unity Biotechnology (senolytics)
• BioAge Labs (aging biomarkers)
• Clever Biosciences (DNA repair)

Pipeline and Programs

| Program | Indication | Stage | Mechanism |
|---------|------------|-------|-----------|
| LB-1 | Alzheimer's Disease | Preclinical | Mitochondrial uncoupling |
| LB-2 | Parkinson's Disease | Preclinical | Protein aggregation modulation |
| LB-3 | Age-related macular degeneration | Preclinical | Senolytic approach |
| LB-4 | Glaucoma | Discovery | Mitochondrial protection |
| LB-SIRT1 | Alzheimer's/Parkinson's | Discovery | SIRT1 activator (NAD+ dependent) |

LB-SIRT1: Sirtuin Activation Program

Life Biosciences is developing an SIRT1 activator program for neurodegenerative diseases:

Rationale:

• SIRT1 is an NAD+-dependent deacetylase that promotes mitochondrial biogenesis, reduces neuroinflammation, and protects against protein aggregation
• In [Parkinson's disease](/diseases/parkinsons-disease), SIRT1 activity is reduced in dopaminergic neurons
• Activation of SIRT1 can deacetylate [α-synuclein](/proteins/alpha-synuclein), reducing its aggregation propensity
• SIRT1 also deacetylates PGC-1α, enhancing mitochondrial biogenesis—a key therapeutic target for PD[@sirt1_activators_pd]

Mechanism:

Differentiation:

• Novel SIRT1 activator with improved brain penetration
• Combined approach: direct SIRT1 activation + NAD+ augmentation potential
• Addresses both protein aggregation and mitochondrial dysfunction

See [SIRT1 Activators for Parkinson's Disease](/mechanisms/sirt1-activators-parkinsons) for detailed mechanism.

LB-1: Alzheimer's Disease Program

The LB-1 program targets mitochondrial dysfunction, which is increasingly recognized as a key contributor to Alzheimer's disease pathogenesis. The approach involves:

• Mechanism: Small molecule mitochondrial uncouplers that restore proper cellular energy metabolism
• Rationale: Mitochondrial dysfunction is observed in Alzheimer's brains, leading to reduced ATP production and increased oxidative stress
• Differentiation: Unlike amyloid-targeting approaches, LB-1 addresses the downstream consequences of protein aggregation

LB-2: Parkinson's Disease Program

The LB-2 program focuses on protein aggregation modulation in Parkinson's disease:

• Mechanism: Modulation of protein homeostasis pathways to reduce toxic protein aggregation
• Target: Alpha-synuclein aggregation and related pathology
• Rationale: Protein aggregation is a hallmark of Parkinson's disease, and current approaches have shown limited efficacy

LB-3: Ophthalmology Program

The LB-3 program applies senolytic approaches to ocular diseases:

• Mechanism: Selective elimination of senescent cells in the retina
• Target: Age-related macular degeneration (AMD)
• Rationale: Senescent cells accumulate in the retina with age and contribute to AMD pathogenesis

Technology Platform

Life Biosciences employs a platform approach targeting multiple hallmarks of aging:

Mitochondrial Dysfunction

Developing mitochondrial uncouplers to restore cellular energy metabolism. The company's mitochondrial platform builds on research showing that:

• [Mitochondrial](/mechanisms/mitochondrial-dysfunction) function declines with age in most tissues
• Restoring mitochondrial function can improve cellular health
• Small molecule uncouplers can improve metabolic parameters in disease models

Protein Homeostasis

Targeting protein aggregation pathways common to neurodegenerative diseases:

• [Amyloid](/mechanisms/amyloid-aggregation)-beta and tau in Alzheimer's
• [Alpha-synuclein](/proteins/alpha-synuclein) in Parkinson's
• TDP-43 in ALS and FTD

Cellular Senescence

Senolytic and senostatic approaches to eliminate or modulate senescent cells:

• Clearing accumulated senescent cells reduces inflammation
• Senostatic approaches modulate the senescence-associated secretory phenotype (SASP)
• Applications in both neurodegeneration and ocular diseases

Research Focus

The company's research focuses on:

Alzheimer's Disease: Targeting amyloid-beta and tau pathology through novel mechanisms

Parkinson's Disease: Addressing alpha-synuclein aggregation and mitochondrial dysfunction

Ophthalmic diseases: Age-related macular degeneration and glaucoma programs

Broader longevity: Platform applicable to multiple age-related conditions

Partnerships and Funding

Life Biosciences has established:

• Academic collaborations: Partnerships with leading research institutions on mechanism of action
• Investor backing: Funding from investors focused on longevity research including:
• Juvenile Diabetes Research Foundation
• Options Health Ventures
• At Last Ventures

Clinical Development Strategy

The company plans to advance programs through:

• Phase 1 trials in healthy volunteers
• Phase 2 proof-of-concept studies in patient populations
• Strategic partnerships for late-stage development and commercialization

Strategic Outlook

Life Biosciences represents an emerging player in the longevity biotechnology space. Key opportunities and challenges include:

Opportunities

• Growing interest in aging research: Increased venture capital and pharmaceutical company interest in longevity
• Unmet medical need: Limited disease-modifying treatments for Alzheimer's and Parkinson's
• Platform potential: Multi-indication approach provides multiple shots on goal

Challenges

• Clinical development risk: Novel mechanisms may face regulatory uncertainty
• Competition: Multiple companies targeting similar mechanisms
• Funding environment: Biotechnology funding can be cyclical

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Life Biosciences, NASDAQ: LIFE (2026)

Life Biosciences, Company Website (2026)

Pathway Diagram

The following diagram shows the key molecular relationships involving Life Biosciences discovered through SciDEX knowledge graph analysis: